Navigating Weight Management: Understanding What’s the Maximum Dose of Wegovy

Last reviewed: June 24, 2026

Last updated: June 24, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The maximum dosage of Wegovy injection is 7.2 mg once weekly — not 2.4 mg, which is where the label stopped for years and where most published summaries still stop. The Wegovy prescribing information now states that for weight reduction in adults, patients who tolerate the 2.4 mg dosage for at least 4 weeks and for whom additional weight reduction is clinically indicated may have the dosage increased to a maximum of 7.2 mg subcutaneously once weekly. That higher strength is dispensed as Wegovy HD. The 2.4 mg dosage remains the recommended maintenance dosage; 7.2 mg is a ceiling, not a destination, and whether anyone goes there is a clinical judgment made by a prescriber, not a milestone to aim for.

The Maximum Depends on Which Indication You Are Being Treated For

Wegovy no longer has one answer to this question, because it no longer has one indication. The label sets maintenance dosages separately for each.

For weight reduction in adults, the maintenance dosage is either 1.7 mg or 2.4 mg once weekly, with 2.4 mg recommended, and the dosage may be increased to a maximum of 7.2 mg once weekly under the conditions above. For cardiovascular risk reduction in adults, the maintenance dosage is either 2.4 mg — recommended — or 1.7 mg once weekly. For weight reduction in pediatric patients aged 12 years and older, the maintenance dosage is either 2.4 mg, recommended, or 1.7 mg once weekly. For noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis in adults, the recommended maintenance dosage is 2.4 mg once weekly, and if that is not tolerated the dosage can be decreased to 1.7 mg once weekly.

So the honest answer to "what is the maximum dose of Wegovy" is: 7.2 mg once weekly, and only within the adult weight-reduction indication. Everywhere else the label tops out at 2.4 mg.

Getting There Is a Fixed Escalation, Not a Choice

Wegovy injection starts at 0.25 mg once weekly for all approved indications, and the label's escalation table runs in four-week blocks: 0.25 mg for weeks 1 through 4, 0.5 mg for weeks 5 through 8, 1 mg for weeks 9 through 12, 1.7 mg for weeks 13 through 16, and from week 17 onward the maintenance dosage appropriate to the indication.

The purpose of that ladder is stated plainly in the label — it reduces the risk of gastrointestinal adverse reactions. The label also builds in a brake: if patients do not tolerate a dose during escalation, prescribers should consider delaying escalation for 4 weeks. Escalation is designed to be slowed when needed, which is the opposite of how people often think about dose increases.

What the 7.2 mg Evidence Actually Shows

The higher dosage is not a guess. Its safety was evaluated in two 72-week double-blind randomized placebo-controlled trials. In the trial described in the label as Study 8, 1,407 patients with obesity — defined as a BMI of 30 kg/m² or greater, with type 2 diabetes excluded — were randomized in a 5:1:1 ratio to Wegovy 7.2 mg, Wegovy 2.4 mg, or placebo once weekly. Mean baseline body weight was 113 kg and mean BMI was 39.9 kg/m².

At week 72, the label reports mean percent changes in body weight of −18.8% with 7.2 mg, −15.5% with 2.4 mg and −3.9% with placebo, with a treatment difference of −3.3% for 7.2 mg versus 2.4 mg. In a companion trial in patients with type 2 diabetes and obesity, the corresponding figures were −13.2% with 7.2 mg, −10.4% with 2.4 mg and −3.8% with placebo.

The safety dataset behind the higher strength is substantial rather than preliminary. The label reports that across those two 72-week trials, 1,311 patients with obesity were exposed in the Wegovy 7.2 mg injection treatment arm, alongside 304 patients exposed to 2.4 mg and 303 exposed to placebo. A maximum dosage carried in a label is a dosage that has been studied at scale under blinded, placebo-controlled conditions, which is exactly what separates it from a number someone escalates to on their own.

Read those numbers carefully. Moving from 2.4 mg to 7.2 mg — tripling the dosage — produced roughly three additional percentage points of weight change on average. That is a real difference and also a modest one, which is precisely why the label conditions the increase on tolerating 2.4 mg first and on additional reduction being clinically indicated.

Wegovy Tablets Have Their Own Maximum

The oral presentation is dosed on a different scale entirely, and the numbers are not interchangeable with the injection. Wegovy tablets are initiated at 1.5 mg once daily for 30 days, then titrated every 30 days: 4 mg on days 31 through 60, 9 mg on days 61 through 90, and 25 mg from day 91 onward. The recommended maintenance dosage of Wegovy tablets is 25 mg orally once daily for cardiovascular risk reduction and weight reduction in adults.

Twenty-five milligrams daily by mouth and 7.2 milligrams weekly by injection are not comparable quantities, because oral semaglutide is absorbed far less efficiently. Anyone comparing the two by the number on the box is comparing the wrong thing.

Higher Is Not Automatically Better

The most common adverse reactions with Wegovy in adults and in pediatric patients aged 12 and older include nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, flatulence, gastroesophageal reflux disease and hair loss. Gastrointestinal effects are dose-related, which is the entire reason the escalation schedule exists.

Wegovy also carries a boxed warning regarding the risk of thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. Labeled warnings include acute pancreatitis, acute gallbladder disease, hypoglycemia with concomitant insulin or insulin secretagogues, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions, diabetic retinopathy complications in patients with type 2 diabetes, heart rate increase, and pulmonary aspiration during general anesthesia or deep sedation. The right dosage is the lowest one that achieves the clinical goal you and your prescriber set.

Compounded Semaglutide Does Not Inherit Wegovy's Numbers

Compounded semaglutide is not an FDA-approved finished product. The FDA states that unapproved versions do not undergo its review for safety, effectiveness and quality before they are marketed, and directs patients to obtain a prescription and fill it at a state-licensed pharmacy.

Because a compounded preparation is made for an individual patient against a specific prescription, the dosages on a brand label do not transfer to it. The only authoritative source for what your preparation contains and how it is to be used is the pharmacy label on the product you were dispensed, together with the clinician who prescribed it. Wegovy and Ozempic are the FDA-approved semaglutide injections, and a compounded preparation is not a generic of either.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

What is the maximum dose of Wegovy?

For weight reduction in adults, the maximum dosage of Wegovy injection is 7.2 mg once weekly, dispensed as Wegovy HD. The label conditions that increase on the patient tolerating the 2.4 mg dosage for at least 4 weeks and on additional weight reduction being clinically indicated. For every other Wegovy indication — cardiovascular risk reduction, pediatric weight reduction, and MASH — the maintenance dosage tops out at 2.4 mg once weekly.

Is Wegovy still 2.4 mg at maintenance?

Yes, 2.4 mg once weekly remains the recommended maintenance dosage for adult weight reduction, with 1.7 mg as the alternative. The 7.2 mg strength sits above it as a maximum, not as a routine target. The label directs prescribers to consider treatment response and tolerability when selecting a maintenance dosage, which means many people are appropriately managed without ever going above 2.4 mg.

How long does it take to reach the maintenance dosage?

Wegovy injection begins at 0.25 mg once weekly and escalates in four-week steps: 0.25 mg for weeks 1 through 4, 0.5 mg for weeks 5 through 8, 1 mg for weeks 9 through 12, 1.7 mg for weeks 13 through 16, and the indication-specific maintenance dosage from week 17 onward. If a dose is not tolerated during escalation, the label advises considering a four-week delay before stepping up.

How much more weight did people lose on 7.2 mg than on 2.4 mg?

In a 72-week trial of 1,407 patients with obesity without type 2 diabetes, the label reports mean body weight changes of −18.8% with 7.2 mg, −15.5% with 2.4 mg and −3.9% with placebo, a difference of −3.3% between the two active dosages. In a companion trial in patients with type 2 diabetes and obesity, the figures were −13.2%, −10.4% and −3.8% respectively.

What is the maximum dose of Wegovy tablets?

The recommended maintenance dosage of Wegovy tablets is 25 mg orally once daily, used for cardiovascular risk reduction and weight reduction in adults. Tablets start at 1.5 mg once daily for 30 days, then titrate every 30 days through 4 mg and 9 mg to 25 mg from day 91 onward. Oral and injectable milligram figures are not comparable, since oral semaglutide is absorbed far less efficiently.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.